Videos

Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.

Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.

Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.

Anouk Hiensch, PhD, discussed results from the PREFERABLE-EFFECT study, which demonstrated that starting a structured, individualized exercise intervention during palliative treatment for metastatic breast cancer decreased fatigue and...

At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...

At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...